BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 1370878)

  • 1. Prostate-specific antigen and prostate-specific acid phosphatase in neuroendocrine cells of prostate cancer.
    Cohen RJ; Glezerson G; Haffejee Z
    Arch Pathol Lab Med; 1992 Jan; 116(1):65-6. PubMed ID: 1370878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
    Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
    Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
    Quek ML; Daneshmand S; Rodrigo S; Cai J; Dorff TB; Groshen S; Skinner DG; Lieskovsky G; Pinski J
    Urology; 2006 Jun; 67(6):1247-52. PubMed ID: 16697447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer-associated markers.
    Chu TM
    Immunol Ser; 1990; 53():339-56. PubMed ID: 1713065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relation of prostatic acid phosphatase and prostate specific antigen with tumour grade in prostatic adenocarcinoma: an immunohistochemical study.
    Ersev A; Ersev D; Turkeri L; Ilker Y; Simsek F; Kullu S; Akdas A
    Prog Clin Biol Res; 1990; 357():129-34. PubMed ID: 1699237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical application of prostatic markers. I. Classification of prostatic tumours using immunohistochemical techniques.
    Svanholm H; Hørder M
    Scand J Urol Nephrol Suppl; 1988; 107():65-70. PubMed ID: 2453920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Endocrine differentiated prostate cancer. Histology and immunohistochemistry].
    Helpap B; Oehler U; Bollmann R
    Pathologe; 1990 Jan; 11(1):18-24. PubMed ID: 1690418
    [No Abstract]   [Full Text] [Related]  

  • 8. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies.
    Casella R; Bubendorf L; Sauter G; Moch H; Mihatsch MJ; Gasser TC
    J Urol; 1998 Aug; 160(2):406-10. PubMed ID: 9679888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin.
    Xing N; Qian J; Bostwick D; Bergstralh E; Young CY
    Prostate; 2001 Jun; 48(1):7-15. PubMed ID: 11391682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum prostatic acid phosphatase activity and prostate specific antigen when the prostate gland is enlarged.
    Jenkins D; Jones RT; Clarke AM
    Med Lab Sci; 1991 Apr; 48(2):161-3. PubMed ID: 1719330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of acid phosphatase in the diagnosis and prognosis of prostatic cancers.
    Rubenstein M; Guinan PD; McKiel CF; Dubin A
    Clin Physiol Biochem; 1988; 6(5):241-52. PubMed ID: 2465864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroendocrine differentiation in prostate cancer.
    Shariff AH; Ather MH
    Urology; 2006 Jul; 68(1):2-8. PubMed ID: 16844446
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
    Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
    Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study.
    Turbat-Herrera EA; Herrera GA; Gore I; Lott RL; Grizzle WE; Bonnin JM
    Arch Pathol Lab Med; 1988 Nov; 112(11):1100-5. PubMed ID: 2460064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen (PSA). A tissue-specific and sensitive tumor marker.
    Mulders TM; Bruning PF; Bonfrer JM
    Eur J Surg Oncol; 1990 Feb; 16(1):37-41. PubMed ID: 1689677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tumor markers of prostate cancer--evaluation of serum PAP and PA].
    Miki M
    Gan No Rinsho; 1985 May; 31(6 Suppl):664-9. PubMed ID: 2411965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical evaluation of a prostate-specific antigen as a serum marker of prostatic cancer].
    Park YC; Kiwamoto H; Nishioka T; Tsujihashi H; Mitsubayashi S; Matsuura T; Akiyama T; Kurita T; Miyamoto T
    Hinyokika Kiyo; 1987 Jun; 33(6):883-8. PubMed ID: 2445188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
    Sciarra A; Di Silverio F
    Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical significance of tumor markers in prostatic carcinoma--comparative study of prostatic acid phosphatase, prostate specific antigen and gamma-seminoprotein].
    Yoshiki T; Okada K; Oishi K; Yoshida O
    Hinyokika Kiyo; 1987 Dec; 33(12):2044-9. PubMed ID: 2452559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Various immunohistochemical markers of precancer and variants of prostate cancer].
    Romanenko AM; Vorob'eva LR
    Arkh Patol; 1995; 57(4):38-41. PubMed ID: 8526754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.